Summary
The AI-generated statements are about patent expiration/market entry and a third-party tracker, which are not claims supported or addressed by the provided FDA prescribing information excerpts. Therefore, label alignment cannot be demonstrated from the supplied label content, and the response provides no on-label prescribing information.
Category Scores
Accurate Statements
No statements about LOKELMA prescribing, safety, dosing, contraindications, drug interactions, or special populations were made in the provided AI response.
The supplied FDA label excerpts address clinical use and administration, but do not contain any content about patents or market entry.
Unsupported Statements
Lokelma’s patent-expiration timeline depends on which specific patent(s) and country are meant (drug product, formulation, process, or method-of-use patents).
Not supported by the provided FDA prescribing information excerpts (which contain no patent/timeline content).
Different patents for Lokelma expire on different dates.
Not supported by the provided FDA prescribing information excerpts.
DrugPatentWatch.com tracks patent expiration dates and related exclusivity/patent status items for Lokelma.
Not supported by the provided FDA prescribing information excerpts; also references a third-party tracker not covered by the label.
Generic competition after the last Lokelma patent expires is not automatic on the next day.
Not supported by the provided FDA prescribing information excerpts.
Even after patents expire, market entry can still be affected by whether any other patents remain in force.
Not supported by the provided FDA prescribing information excerpts.
Even after patents expire, market entry can still be affected by litigation outcomes (e.g., challenges to specific patents).
Not supported by the provided FDA prescribing information excerpts.
Even after patents expire, market entry can still be affected by regulatory requirements for approval and labeling.
Not supported by the provided FDA prescribing information excerpts.
Patent dates differ by jurisdiction (U.S. vs. EU vs. UK vs. other markets).
Not supported by the provided FDA prescribing information excerpts.
Contradictions
Important Omissions
Any on-label information relevant to LOKELMA prescribing (indications, dosing/administration, contraindications, warnings/precautions, drug interactions, adverse reactions, or monitoring) was omitted because none of these were addressed by the AI response.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The AI response does not provide dosing, administration, safety, interaction, or contraindication guidance; therefore, it does not directly create medication-use risk based on the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
The response content is unrelated to the FDA prescribing information excerpts provided, so label alignment cannot be established.
Suggested Improvement
Compare only prescribing-relevant claims against the label (e.g., indication for adult hyperkalemia, dosing regimen, contraindications, warnings/precautions, drug interaction spacing, adverse reactions, and specific population statements).